Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Aug;23(8):920-928.
doi: 10.1016/j.jmoldx.2021.05.003. Epub 2021 May 19.

Real-Life Head-to-Head Comparison of Performance of Two High-Throughput Automated Assays for the Detection of SARS-CoV-2 RNA in Nasopharyngeal Swabs: The Alinity m and cobas 6800 SARS-CoV-2 Assays

Affiliations
Comparative Study

Real-Life Head-to-Head Comparison of Performance of Two High-Throughput Automated Assays for the Detection of SARS-CoV-2 RNA in Nasopharyngeal Swabs: The Alinity m and cobas 6800 SARS-CoV-2 Assays

Rok Kogoj et al. J Mol Diagn. 2021 Aug.

Abstract

The Alinity m (Abbott Molecular, Des Plaines, IL) automated molecular analyzer allows continuous loading of samples and sample-to-result molecular detection of several microorganisms. The detection of SARS-CoV-2 by the Alinity m was compared with that of the cobas 6800 (Roche Molecular Systems, Branchburg, NJ; standard comparator) in a manufacturer-independent clinical evaluation on 2157 consecutive nasopharyngeal swab samples. Valid initial results on Alinity m and cobas 6800 were obtained from 2129 (98.7%) and 2157 (100%) samples, respectively. The overall percent agreement (95% CI) was 98.3% (2092/2129 [97.6%-98.7%]); positive percent agreement, 100% (961/961 [99.6%-100%]); negative percent agreement, 96.8% (1131/1168 [95.7%-97.7%]); and high κ value, 0.965 (0.954-0.976). There were 37 discordant results on Alinity m and, based on discordant analyses, including previous and/or follow-up PCR results, 22 could be considered analytically true positive with high probability. Due to a lack of additional information and an inability to perform repeated/further testing, the status of the remaining 15 discordant results remained unresolved. The throughput of the two analyzers was compared using testing on 564 samples in parallel across two 8-hour shifts in clinical practice. The turnaround times were compared using processing of 94 routine samples in parallel on each working day for 5 consecutive days. The two analyzers showed similar performance, with certain differences that have potential importance in some laboratory settings.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Time curves visualizing the release dynamics of the final SARS-CoV-2 RNA results from the Alinity m (Abbott Molecular, Des Plaines, IL) and cobas 6800 (Roche Molecular Systems, Branchburg, NJ) analyzers in the testing of 564 nasopharyngeal swab samples in parallel across two 8-hour shifts. The sample-handling times (dark), instrument-handling times (light), and total hands-on times of each analyzer were measured by two independent observers (R.K. and A.O.V).

Similar articles

Cited by

References

    1. Ravi N., Cortade D.L., Ng E., Wang S.X. Diagnostics for SARS-CoV-2 detection: a comprehensive review of the FDA-EUA COVID-19 testing landscape. Biosens Bioelectron. 2020;165:112454. - PMC - PubMed
    1. Loeffelholz M.J., Tang Y.W. Laboratory diagnosis of emerging human coronavirus infections—the state of the art. Emerg Microbes Infect. 2020;20:1–26. - PMC - PubMed
    1. Arena F., Pollini S., Rossolini G.M., Margaglione M. Summary of the available molecular methods for detection of SARS-CoV-2 during the ongoing pandemic. Int J Mol Sci. 2021;22:1298. - PMC - PubMed
    1. Poljak M., Korva M., Knap Gašper N., Fujs Komloš K., Sagadin M., Uršič T., Avšič Županc T., Petrovec M. Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic. J Clin Microbiol. 2020;58:e00599-20. - PMC - PubMed
    1. Lieberman J.A., Pepper G., Naccache S.N., Huang M.L., Jerome K.R., Greninger A.L. Comparison of commercially available and laboratory-developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories. J Clin Microbiol. 2020;58:e00821-20. - PMC - PubMed

Publication types